Bracco highlights MultiHance results, launches MDCT protocol software

By staff writers
March 6, 2014

Bracco Imaging is highlighting new data on the use of gadobenate dimeglumine for breast MRI at a company-sponsored symposium at ECR 2014 in Vienna.

In 2011, a study, titled "Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast (DETECT trial)," compared the gadobenate dimeglumine contrast agent from Bracco with Magnevist, the gadopentetate dimeglumine contrast agent from Bayer HealthCare Pharmaceuticals. Bracco sponsored the study.

A new analysis of the data collected during the DETECT study, recently published in the Journal of Magnetic Resonance Imaging, also compared the diagnostic performance of MRI with conventional imaging techniques. The results showed highly significant superiority in malignant lesion detection rate for MRI enhanced with 0.1 mmol/kg gadobenate dimeglumine compared with mammography, ultrasound, and mammography and ultrasound combined.

The researchers reported lower false-positive detection rates with gadobenate dimeglumine-enhanced MRI than with both gadopentetate dimeglumine-enhanced MRI and conventional imaging techniques.

The new results support the value of MRI in detecting breast cancer, said Dr. Alberto Spinazzi, Bracco's head of global medical and regulatory affairs, adding that the findings also indicate that improved diagnostic performance on breast MRI may be achieved, if MRI contrast agents with high relaxivity are used.

In other company news, Bracco has also launched a new tailored protocol software package for multidetector-row CT (MDCT).

The software, available on Bracco's website, was developed by a group of radiologists and tailors contrast-enhanced MDCT scanning parameters to individual patients. It can be applied to a database of contrast-enhanced MDCT protocols that contains more than 500 combinations of CT scanners and CT applications for Bracco's tri-iodinated, nonionic contrast agent, Iomeron 400, as well as iopamidol in the 370 mg/mL concentration, the company said.

Nordion, Bracco ink supply deal
Canadian radioisotope firm Nordion and Bracco Imaging have signed a two-year contract to supply U.S. subsidiary Bracco Diagnostics with strontium-82.
Bracco signs DoseMonitor distribution deal
Bracco Diagnostic has signed an agreement with PHS Technologies Group to promote, market, and distribute DoseMonitor globally.
Bracco debuts syringe packs for CT contrast
Contrast developer Bracco Diagnostics said it is making syringe packs with spikes available for use with its CT contrast delivery systems.
Bracco's SonoVue gets approval in Brazil
Bracco Imaging announced that the Brazilian National Health Surveillance Agency has approved its SonoVue ultrasound contrast agent.
Bracco to discontinue some barium products
Bracco Diagnostics is planning to discontinue some of its barium products starting in October, the company said in a letter to customers.

Copyright © 2014

Last Updated np 3/6/2014 11:48:56 AM